Kennedy Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Kennedy Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-11,978	Closed	-$189K	–	760
2024 Q1	$189K	Buy	+11,978	New	+$165K	﹤0.01%	708
2023 Q4	–	Sell	-156,475	Closed	-$3.14M	–	724
2023 Q3	$3.14M	Buy	156,475 +4,178	+3%	+$106K	0.08%	377
2023 Q2	$4.3M	Sell	152,297 -96,143	-39%	-$2.31M	0.1%	324
2023 Q1	$4.27M	Buy	248,440 +13,833	+6%	+$280K	0.13%	286
2022 Q4	$4.72M	Sell	234,607 -8,396	-3%	-$181K	0.13%	282
2022 Q3	$5.26M	Buy	243,003 +121,408	+100%	+$3.32M	0.15%	233
2022 Q2	$3.42M	Buy	+121,595	New	+$3.22M	0.1%	343

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Kennedy Capital Management's ZNTL Position: Q2 2024 in Review

Kennedy Capital Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2024, closing a stake of 11,978 shares — an estimated $189K sold.

Kennedy Capital Management first reported a position in ZNTL in Q2 2022 and held it in 7 quarters. The position peaked at $5.26M in Q3 2022. 145 funds tracked by Wall St. Rank hold ZNTL as of Q2 2024.

Kennedy Capital Management reported no remaining Zentalis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Kennedy Capital Management sold 11,978 Zentalis Pharmaceuticals shares in Q2 2024, an estimated $189K.
Kennedy Capital Management first reported a position in Zentalis Pharmaceuticals in Q2 2022 and held it in 7 quarters.
Kennedy Capital Management's Zentalis Pharmaceuticals position peaked at $5.26M in Q3 2022.
145 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2024.

Based on Kennedy Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.